USPTO serial 77256646
INJECTABLES EXCELLENCE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- SWAIN, MICHELE LYNN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with INJECTABLES EXCELLENCE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Marcia Ireland Rosenfeld
MARCIA IRELAND ROSENFELD MCDONNELL BOEHNEN HULBERT & BERGOFF LLP300 S WACKER DR STE 3200CHICAGO, IL 60606-6709UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals, namely, alkalizing agents, analgesics and anesthetics, antacids, anticholinergics, antihistamines, anti-infectives, anti-inflammatory agents, anticonvulsants, antidotes, antiemetics, antipsychotics, anxiolytics, blood modifiers, bronchodialators, cardiovasculars, diuretics, hormones, diluents, electrolytes, vitamins, oncolytics, immunosuppressive agents, transplantation agents, imaging agents, vascular targeting agents, and sensitizing agents for chemotherapy-resistant tumors; Pre-filled syringes sold filled with alkalizing agents; pre-filled syringes sold filled with analgesics; pre-filled syringes sold filled with anesthetics; pre-filled syringes sold filled with antacids; pre-filled syringes sold filled with anticholinergics; pre-filled syringes sold filled with antihistamines; pre-filled syringes sold filled with anti-infectives; pre-filled syringes sold filled with anti-inflammatory agents; pre-filled syringes sold filled with anticonvulsants; pre-filled syringes sold filled with antidotes; pre-filled syringes sold filled with antiemetics; pre-filled syringes sold filled with antipsychotics; pre-filled syringes sold filled with anxiolytics; pre-filled syringes sold filled with blood modifiers; pre-filled syringes sold filled with bronchodialators; pre-filled syringes sold filled with cardiovasculars; pre-filled syringes sold filled with diuretics; pre-filled syringes sold filled with hormones; pre-filled syringes sold filled with diluents; pre-filled syringes sold filled with electrolytes; pre-filled syringes sold filled with vitamins; pre-filled syringes sold filled with oncolytics; pre-filled syringes sold filled with immunosuppressive agents; pre-filled syringes sold filled with transplantation agents; pre-filled syringes sold filled with imaging agents; pre-filled syringes sold filled with vascular targeting agents; pre-filled syringes sold filled with sensitizing agents for chemotherapy-resistant tumors; Safety syringe devices sold filled with alkalizing agents; safety syringe devices sold filled with analgesics; safety syringe devices sold filled with anesthetics; safety syringe devices sold filled with antacids; safety syringe devices sold filled with anticholinergics; safety syringe devices sold filled with antihistamines; safety syringe devices sold filled with anti-infectives; safety syringe devices sold filled with anti-inflammatory agents; safety syringe devices sold filled with anticonvulsants; safety syringe devices sold filled with antidotes; safety syringe devices sold filled with antiemetics; safety syringe devices sold filled with antipsychotics; safety syringe devices sold filled with anxiolytics; safety syringe devices sold filled with blood modifiers; safety syringe devices sold filled with bronchodialators; safety syringe devices sold filled with cardiovasculars; safety syringe devices sold filled with diuretics; safety syringe devices sold filled with hormones; safety syringe devices sold filled with diluents; safety syringe devices sold filled with electrolytes; safety syringe devices sold filled with vitamins; safety syringe devices sold filled with oncolytics; safety syringe devices sold filled with immunosuppressive agents; safety syringe devices sold filled with transplantation agents; safety syringe devices sold filled with imaging agents; safety syringe devices sold filled with vascular targeting agents; safety syringe devices sold filled with sensitizing agents for chemotherapy-resistant tumors; Pharmaceuticals for treatment of cancer; pharmaceuticals to treat vascular diseases; Drug delivery systems sold as an integral component of drugs, namely, intradermal injection system for injection of anesthetics; Injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases; injectable drugs and therapeutic solutions for the treatment of psychotic disorders; injectable drugs and therapeutic solutions for the treatment of pain; injectable drugs and therapeutic solutions for the treatment of allergies; injectable drugs and therapeutic solutions for the treatment of infections; injectable drugs and therapeutic solutions for the treatment of cardiovascular disease; injectable drugs and therapeutic solutions for the treatment of kidney disease; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies; injectable drugs and therapeutic solutions for the treatment of heartburn; injectable drugs and therapeutic solutions for the treatment of anxiety; injectable drugs and therapeutic solutions for immunosuppression; injectable drugs and therapeutic solutions for imaging; injectable drugs and therapeutic solutions for the treatment of seizures; Injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of psychotic disorders sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of pain sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of allergies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of infections sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of cardiovascular disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of kidney disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of heartburn sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of anxiety sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for immunosuppression sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for imaging sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of seizures sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 31, 2011 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 31, 2011 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 6, 2011 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 5, 2011 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Mar 28, 2011 | EXT5 | SOU EXTENSION 5 FILED | — |
| Mar 28, 2011 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 5, 2010 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 4, 2010 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Sep 30, 2010 | EXT4 | SOU EXTENSION 4 FILED | — |
| Sep 30, 2010 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 30, 2010 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 29, 2010 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Mar 25, 2010 | EXT3 | SOU EXTENSION 3 FILED | — |
| Mar 25, 2010 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 14, 2009 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 13, 2009 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 30, 2009 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 30, 2009 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 30, 2009 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 30, 2009 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 30, 2009 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 30, 2008 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 8, 2008 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 18, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 4, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 3, 2008 | ALIE | ASSIGNED TO LIE | — |
| Jun 3, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 27, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 27, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 27, 2008 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 27, 2007 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2007 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2007 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2007 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2007 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2007 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 26, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 20, 2007 | NWAP | NEW APPLICATION ENTERED | — |